My first earnings short-squeeze trade idea is biotech player BioMarin Pharmaceutical (BMRN - Get Report), which is set to report its numbers on Thursday after the market close. This company develops and commercializes pharmaceuticals for serious diseases and medical conditions. Wall Street analysts, on average, expect BioMarin Pharmaceutical to report revenue of $115.30 million on a loss of 11 cents per share.
If you're looking for a technically strong stock that's within range of hitting a new 52-week high post-earnings, then make sure to take a hard look at shares of BioMarin Pharmaceutical. This stock is currently trading just one point off its 52-week high of $38.95 as we head closer to its quarterly earnings report.The current short interest as a percentage of the float for BioMarin Pharmaceutical is notable at 7%. That means that out of the 113.76 million shares in the tradable float, 7.93 million shares are sold short by the bears. >>6 Drug Stocks Unworthy of a Biotech Bull Market From a technical perspective, BMRN is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending strong for months, with shares consistently making higher lows and higher highs, which is bullish price action. Now this stock is within range of triggering a big post-earnings breakout, and the upside volume patterns during the past few weeks have been ridiculously strong. If you're bullish on BMRN, I would look for long-biased trades following its report if the stock takes out $38.95 to $40 a share with strong volume. Look for volume that's tracking in close to or above its three-month average of 991,058 shares. If those levels get taken out with volume, it would be very bullish since it will push BMRN into all-time high territory. I would look for a large spike of 10% or more post-earnings if that breakout gets triggered. I would avoid BMRN or look for short-biased trades after they report if the stock fails to trigger that breakout and then drops below some near-term support at $37 a share with volume. I would target a drop back towards its 50-day moving average of $35.26 a share, or possibly lower if the bears slam this down post-earnings.